Molecular Formula | C20H33NO3S |
Molar Mass | 367.55 |
Density | 1.038±0.06 g/cm3(Predicted) |
Boling Point | 566.1±50.0 °C(Predicted) |
Solubility | Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 25 mg/ml) |
Appearance | Pale yellow oil. |
Color | Yellow |
pKa | 3.31±0.10(Predicted) |
Storage Condition | -15°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
In vitro study | Arazine (2 hours) inhibits ATPγS induced CXCL1, CXCL8 and CCL2 production as a dose-dependent manner in HMEC-1 cell. Arazine (10–100 μM;8 hours) significantly affects the HMEC-1 cell viability as measured by trypan blue exclusion in HMEC-1 cell. |
In vivo study | Arazine (AFC) (2,000μg/20μl; applied on ear) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with a 50% effective dose (ED 50 ) of 55±12μg/20μl. Animal Model: TPA-induced ear acute inflammation in mouse Dosage: 2000μg/20μl Administration: 2000μg/20μl; Applied on ear Result: Inhibited ear edema, as measured by ear weight. |
Hazard Class | IRRITANT |